terazosin


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to terazosin: terazosin HCl

terazosin

 [ter-a´zo-sin]
an alpha1-adrenergic blocking agent used as the hydrochloride salt in treatment of hypertension and benign prostatic hyperplasia, administered orally.

terazosin

/ter·a·zo·sin/ (ter-a´zo-sin) an alpha used as the hydrochloride salt in the treatment of hypertension and of benign prostatic hyperplasia.

terazosin

[ter′əzō′sin]
a drug approved for the treatment of benign prostatic hypertrophy. It acts by relaxing the smooth muscle fibers of the prostate through its alpha receptor blockage mechanisms. It is also used alone or in combination for the treatment of hypertension.

terazosin

Hytrin® An antihypertensive quinazoline that selectively blocks post-synaptic α1-adrenergic receptors Clinical effects ↓ Peripheral vascular resistance due to arterial and venous dilation, ↑ HDL-C; may improve glucose tolerance and CHF; it provides symptomatic relief in BPH, ↑urine flow, ↓ muscle tone in bladder Adverse effects Hypotension, vertigo, headache, drowsiness, weakness, palpitations. Cf Proscar.

terazosin

A selective alpha-adrenergic blocker drug used to treat high blood pressure and to relieve the symptoms of simple enlargement of the PROSTATE GLAND (benign prostatic hyperplasia). A brand name is Hytrin.
References in periodicals archive ?
Doxazosin and terazosin may be considered second-line Alpha-2 agonists Clonidine may reduce agitation.
Since the chemical structure of terazosin is also a C-terminal furan-contained structure [16], which is considered to be one of classic structures of potential 20S proteasome inhibitors.
Abbott's patent was directed to crystalline forms of terazosin hydrochloride, which is the active ingredient in Hytrin.
Paul suffers from high blood pressure and his doctor had placed him on a course of cholesterol-lowering drugs, Simvastatin and Terazosin.
generic terazosin hydrochloride off the market pending a resolution of
In this open-label, nonrandomized, 12-week retrospective study, 60 patients were assigned to four treatment groups: no treatment, treatment with benzatropine 2 mg/day, treatment with terazosin (an [[alpha].
Pathophysiolgy of autonomic dysreflexia; long-term treatment with terazosin in adult and pediatric spinal cord injury patients manifesting recurrent dysreflexic episodes.